Shakespeare Wealth Management LLC Cuts Holdings in Johnson & Johnson $JNJ

Shakespeare Wealth Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 13.2% during the second quarter, Holdings Channel.com reports. The firm owned 3,181 shares of the company’s stock after selling 483 shares during the quarter. Shakespeare Wealth Management LLC’s holdings in Johnson & Johnson were worth $486,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. purchased a new stake in Johnson & Johnson during the 1st quarter worth about $218,000. Smart Money Group LLC boosted its position in shares of Johnson & Johnson by 6.5% during the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after acquiring an additional 407 shares in the last quarter. United Bank increased its holdings in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Johnson & Johnson by 8.2% during the 1st quarter. Assetmark Inc. now owns 85,662 shares of the company’s stock worth $14,206,000 after acquiring an additional 6,501 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on JNJ shares. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. UBS Group increased their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Scotiabank began coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target on the stock. Finally, Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Stock Up 0.4%

JNJ opened at $203.88 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $206.94. The business has a 50 day moving average price of $188.25 and a two-hundred day moving average price of $171.67. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $491.21 billion, a PE ratio of 19.68, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.